Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
Tango missteps in PRMT5
The company abandons TNG908, but is still all in on the troubled target.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
ESMO 2024 – degraders disappoint again
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
